Keyphrases
Clinical Evidence
100%
Somatostatin Receptor Antagonist
100%
111In-DTPA-octreotide
50%
Tumor
33%
Biodistribution
33%
Neuroendocrine Tumor
33%
Same Patient
16%
Somatostatin Receptor
16%
Receptor-mediated
16%
After Injection
16%
No Adverse Effect
16%
Tumor Uptake
16%
Peptide Receptor
16%
Renal Uptake
16%
Somatostatin Receptor Agonists
16%
Octreotide Scan
16%
Injected Activity
16%
Metastatic Papillary Thyroid Carcinoma
16%
Medicine and Dentistry
Indium 111
100%
Somatostatin Receptor Antagonist
100%
Tetraxetan
55%
Neoplasm
33%
Pentetic Acid
33%
Biodistribution
22%
Neuroendocrine Tumor
22%
Octreotide
22%
Peptide Receptor
11%
Somatostatin Receptor Agonist
11%
Octreotide Scan
11%
Thyroid Carcinoma
11%
Somatostatin Receptor
11%
Adverse Effect
11%
Pharmacology, Toxicology and Pharmaceutical Science
Indium 111
100%
Somatostatin Receptor Antagonist
100%
Tetraxetan
55%
Pentetic Acid
33%
Neoplasm
33%
Octreotide
33%
Biodistribution
22%
Neuroendocrine Tumor
22%
Preclinical Study
11%
Somatostatin Receptor
11%
Receptor
11%
Thyroid Carcinoma
11%
Somatostatin Receptor Agonist
11%